Seek Returns logo

ABT vs. ASND: A Head-to-Head Stock Comparison

Updated

Here’s a clear look at ABT and ASND, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.

Company Overview

ABT dominates in value with a market cap of 231.49 billion USD, eclipsing ASND’s 9.55 billion USD by roughly 24.25×.

ABT’s beta of 0.74 points to much larger expected swings compared to ASND’s calmer 0.40, suggesting both higher upside and downside potential.

ASND is an ADR, letting U.S. buyers tap its non-U.S. business directly, unlike ABT, which is purely domestic.

SymbolABTASND
Company NameAbbott LaboratoriesAscendis Pharma A/S
CountryUSDK
SectorHealthcareHealthcare
IndustryMedical - DevicesBiotechnology
CEOMr. Robert B. FordMr. Jan Moller Mikkelsen
Price133.05 USD158.1 USD
Market Cap231.49 billion USD9.55 billion USD
Beta0.740.40
ExchangeNYSENASDAQ
IPO DateMarch 17, 1980January 28, 2015
ADRNoYes

Performance Comparison

This chart compares the performance of ABT and ASND over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).

Hover over the lines to see the investment’s value and total return (%) at specific dates.

Data is adjusted for dividends and splits.

Valuation Metrics Comparison

The section examines key financial ratios to assess the valuation of ABT and ASND based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.

  • ASND shows a negative P/E of -24.55, highlighting a year of losses, whereas ABT at 17.22 trades on solid profitability.
  • ASND shows a negative forward PEG of -2.23, signaling expected earnings contraction, while ABT at 1.73 maintains analysts’ projections for stable or improved profits.
  • ASND carries a sub-zero price-to-book ratio of -44.20, indicating negative equity. In contrast, ABT (P/B 2.48) has positive book value.
  • ASND reports a negative Price-to-Free Cash Flow ratio of -27.43, showing a cash flow shortfall that could threaten its operational sustainability, while ABT at 34.77 maintains positive cash flow.
SymbolABTASND
Price-to-Earnings Ratio (P/E, TTM)17.22-24.55
Forward PEG Ratio (TTM)1.73-2.23
Price-to-Sales Ratio (P/S, TTM)5.4722.89
Price-to-Book Ratio (P/B, TTM)2.48-44.20
Price-to-Free Cash Flow Ratio (P/FCF, TTM)34.77-27.43
EV-to-EBITDA (TTM)22.97-35.74
EV-to-Sales (TTM)5.6323.78
EV-to-Free Cash Flow (TTM)35.78-28.50

Dividend Comparison

ABT delivers a 1.71% dividend yield, blending income with growth, whereas ASND appears to retain its profits, possibly to fund operations, R&D, or other growth initiatives.

SymbolABTASND
Dividend Yield (TTM)1.71%0.00%

Financial Strength Metrics Comparison

This section dives into the financial resilience of ABT and ASND, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.

  • ASND posts a quick ratio of 0.71, indicating limited coverage of short-term debts from its most liquid assets—while ABT at 1.27 enjoys stronger liquidity resilience.
  • ASND has negative equity (debt-to-equity ratio -4.46), suggesting asset shortfalls, whereas ABT at 0.14 preserves healthier equity coverage.
  • ABT meets its interest obligations (ratio 15.39). In stark contrast, ASND’s negative ratio (-3.72) means its operating earnings (EBIT) don't cover basic operations, let alone interest, signaling serious financial trouble.
SymbolABTASND
Current Ratio (TTM)1.781.04
Quick Ratio (TTM)1.270.71
Debt-to-Equity Ratio (TTM)0.14-4.46
Debt-to-Assets Ratio (TTM)0.160.80
Interest Coverage Ratio (TTM)15.39-3.72